全球主动监测全球行动计划3倡议中一致的活检质量与Gleason分级:未来研究的先决条件
在Movember基金会全球行动计划前列腺癌主动监测(GAP3)倡议中,25个中心协作标准化低危前列腺癌(PCa)男性的主动监测(AS)方案,建立了包含全球15000余例患者数据的集中式PCa AS数据库。通过对15个GAP3中心445例活检的集中病理审查评估不同队列间组织病理学的可比性,结果显示审查一致率为89%,一致性中等(κ=0.56),平均活检芯长度在各分析队列间相似,新近确立的高度不良病理(包括筛状和/或导管内癌)在审查活检中占3.6%。结论认为集中病理审查显示15个GAP3中心间组织病理学可比且高危特征频率低,使得无需校正即可进一步数据分析以制定统一的全球AS指南。
要点
- 集中病理审查445例活检显示15个GAP3中心间组织病理学可比,一致率89%,κ=0.56。
- 审查中3.6%的活检观察到筛状和/或导管内癌等高度不良病理。
- 平均活检芯长度在各分析队列间相似,支持无需校正即可进一步数据分析。
核心结论
- 集中病理审查445例活检显示15个GAP3中心间组织病理学可比,高危特征频率低,使得无需校正即可进一步数据分析以制定统一的全球AS指南。
研究设计与样本
- Movember基金会全球行动计划前列腺癌主动监测(GAP3)倡议,25个中心协作标准化低危PCa的AS方案,建立包含全球15000余例患者数据的集中式PCa AS数据库;对15个GAP3中心的445例活检进行集中病理审查以评估不同队列间组织病理学的可比性。
主要发现
- 审查中1级组(Gleason评分6)占85%,≥2级组(Gleason评分≥7)占15%,审查一致率为89%,一致性中等(κ=0.56)。
- 平均活检芯长度在各分析队列间相似。
- 新近确立的高度不良病理(包括筛状和/或导管内癌)在审查活检中占3.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Within the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative, 25 centers across the globe collaborate to standardize active surveillance (AS) protocols for men with low-risk prostate cancer (PCa). A centralized PCa AS database, comprising data of more than 15000 patients worldwide, was created. Comparability of the histopathology between the different cohorts was assessed by a centralized pathology review of 445 biopsies from 15 GAP3 centers. Grade group 1 (Gleason score 6) in 85% and grade group ≥2 (Gleason score ≥7) in 15% showed 89% concordance at review with moderate agreement (κ=0.56). Average biopsy core length was similar among the analyzed cohorts. Recently established highly adverse pathologies, including cribriform and/or intraductal carcinoma, were observed in 3.6% of the reviewed biopsies. In conclusion, the centralized pathology review of 445 biopsies revealed comparable histopathology among the 15 GAP3 centers with a low frequency of high-risk features. This enables further data analyses-without correction-toward uniform global AS guidelines for men with low-risk PCa. PATIENT SUMMARY: Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative combines data from 15000 men with low-risk prostate cancer (PCa) across the globe to standardize active surveillance protocols. Histopathology review confirmed that the histopathology was consistent with low-risk PCa in most men and comparable between different centers.
引用
- van der Kwast TH, Helleman J, Nieboer D, et al. Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. Eur Urol Oncol. 2018. PMID: 31200849. doi:10.1016/j.euo.2018.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。